1. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
by Jorge E. Cortes, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla-Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, and Michele Baccarani
Blood
Volume 117(21):
May 26, 2011
©2011 by American Society of Hematology

2. Nilotinib response rates in patients entering the study with imatinib intolerance. *Patients who did not have complete hematologic response at baseline.
Nilotinib response rates in patients entering the study with imatinib intolerance. *Patients who did not have complete hematologic response at baseline.
Jorge E. Cortes et al. Blood 2011;117:
©2011 by American Society of Hematology